Human β-Secretase (BACE1) Inhibitor Screening Kit (Fluorometric)-K720

MILPITAS, Calif. - April 16, 2018 - PRLog -- β-Secretase (Beta-site amyloid precursor protein (APP) cleaving enzyme 1/BACE1), participates in the initial cleavage of amyloid precursor-APP generating two soluble N-terminal and C-terminal fragments. Another secretase isozyme, γ-Secretase, cleaves C-terminal fragment producing amyloid β. Accumulation of amyloid β in brain results in the formation of amyloid plaques, which contribute in the development of Alzheimer's disease (AD) in humans. Therefore, screening for novel and specific inhibitors of human β-Secretase (BACE1) has become critical in Alzheimer's Disease-related drug discovery research. In BioVision's Human β-Secretase (BACE1) Inhibitor Screening Kit, human BACE1 cleaves a quenched substrate, specific for BACE1, generating a product with high fluorescence that can be measured at Ex/Em= 435/500 nm. In the presence of BACE1 Inhibitor (control included in this kit), the enzymatic cleavage is impeded and could be used to screen for new inhibitor compounds. The assay is high-throughput adaptable and can be completed in less than 1 hr.

Figure: Inhibition of Human β-Secretase (BACE1) activity by BACE1 Inhibitor (IC50 = 1 nM). Assay was performed using BioVision's K720.

For detailed information on this assay, visit: https://www.biovision.com/human-secretase-bace1-inhibitor...